Oral versus intravenous antibiotic treatment for bone and joint infections (OVIVA): study protocol for a randomised controlled trial
Authors:
- Ho Kwong LiHLHo Kwong Li
- Matthew ScarboroughMSMatthew Scarborough
- Rhea ZambellasRZRhea Zambellas
- Cushla CooperCCCushla Cooper
- Ines RombachIRInes Rombach
- A. Sarah WalkerAWA. Sarah Walker
- Benjamin A. LipskyBLBenjamin A. Lipsky
- Andrew BriggsABAndrew Briggs
- Andrew SeatonASAndrew Seaton
- Bridget AtkinsBABridget Atkins
- Andrew WoodhouseAWAndrew Woodhouse
- Anthony BerendtABAnthony Berendt
Open Access
- 21 December 2015
- journal article
- research article
- Published by Springer Nature in Trials
- Vol. 16 (1) , 1-13
Abstract
Bone and joint infection in adults arises most commonly as a complication of joint replacement surgery, fracture fixation and diabetic foot infection. The associated morbidity can be devastating to patients and costs the National Health Service an estimated £20,000 to £40,000 per patient. Current standard of care in most UK centres includes a prolonged course (4–6 weeks) of intravenous antibiotics supported, if available, by an outpatient parenteral antibiotic therapy service. Intravenous therapy carries with it substantial risks and inconvenience to patients, and the antibiotic-related costs are approximately ten times that of oral therapy. Despite this, there is no evidence to suggest that oral therapy results in inferior outcomes. We hypothesise that, by selecting oral agents with high bioavailability, good tissue penetration and activity against the known or likely pathogens, key outcomes in patients managed primarily with oral therapy are non-inferior to those in patients treated by intravenous therapy. The OVIVA trial is a parallel group, randomised (1:1), un-blinded, non-inferiority trial conducted in thirty hospitals across the UK. Eligible participants are adults (>18 years) with a clinical syndrome consistent with a bone, joint or metalware-associated infection who have received ≤7 days of intravenous antibiotic therapy from the date of definitive surgery (or the start of planned curative therapy in patients treated without surgical intervention). Participants are randomised to receive either oral or intravenous antibiotics, selected by a specialist infection physician, for the first 6 weeks of therapy. The primary outcome measure is definite treatment failure within one year of randomisation, as assessed by a blinded endpoint committee, according to pre-defined microbiological, histological and clinical criteria. Enrolling 1,050 subjects will provide 90 % power to demonstrate non-inferiority, defined as less than 7.5 % absolute increase in treatment failure rate in patients randomised to oral therapy as compared to intravenous therapy (one-sided alpha of 0.05). If our results demonstrate non-inferiority of orally administered antibiotic therapy, this trial is likely to facilitate a dramatically improved patient experience and alleviate a substantial financial burden on healthcare services. ISRCTN91566927 - 14/02/2013Keywords
Funding Information
- Health Technology Assessment Programme (GB) (11/36/29)
This publication has 29 references indexed in Scilit:
- A financial analysis of revision hip arthroplastyThe Journal of Bone and Joint Surgery. British volume, 2012
- The microbiology of chronic osteomyelitis: Prevalence of resistance to common empirical anti-microbial regimensJournal of Infection, 2010
- Treatment approaches to prosthetic joint infections: results of an Emerging Infections Network surveyDiagnostic Microbiology and Infectious Disease, 2009
- Randomized Control Trial Comparing Oral Amoxicillin-clavulanate and Ofloxacin With Intravenous Ceftriaxone and Amikacin as Outpatient Therapy in Pediatric Low-risk Febrile NeutropeniaJournal of Pediatric Hematology/Oncology, 2009
- Systemic Antimicrobial Therapy in OsteomyelitisSeminars in Plastic Surgery, 2009
- Is prolonged systemic antibiotic treatment essential in two-stage revision hip replacement for chronic Gram-positive infection?The Journal of Bone and Joint Surgery. British volume, 2009
- Antibiotic treatment for pyelonephritis in children: multicentre randomised controlled non-inferiority trialBMJ, 2007
- Outpatient parenteral antimicrobial therapy (OPAT): is it safe for selected patients to self-administer at home? A retrospective analysis of a large cohort over 13 yearsJournal of Antimicrobial Chemotherapy, 2007
- Effectiveness of early switch from intravenous to oral antibiotics in severe community acquired pneumonia: multicentre randomised trialBMJ, 2006
- Oral Cefixime Is Similar to Continued Intravenous Antibiotics in the Empirical Treatment of Febrile Neutropenic Children with CancerClinical Infectious Diseases, 2001